Last reviewed · How we verify
Normal Treatment
Normal treatment involves the administration of a standard, established therapy.
Normal treatment involves the administration of a standard, established therapy. Used for Management of various conditions.
At a glance
| Generic name | Normal Treatment |
|---|---|
| Sponsor | Fundación Canaria de Investigación Sanitaria |
| Modality | Small molecule |
| Therapeutic area | General Medicine |
| Phase | FDA-approved |
Mechanism of action
Normal treatment is a standard approach to managing a condition, often involving a combination of medications and lifestyle modifications. The specific components of normal treatment can vary depending on the condition being treated and the individual patient's needs.
Approved indications
- Management of various conditions
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- The Effectiveness of Neurodevelopmental Treatment (Bobath) and Functional Physiotherapy in Children With Cerebral Palsy. (NA)
- DDAVP for Pituitary Adenoma (NA)
- Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Normal Treatment CI brief — competitive landscape report
- Normal Treatment updates RSS · CI watch RSS
- Fundación Canaria de Investigación Sanitaria portfolio CI